Is treating post-ACS depression worth it?
- PDF / 114,576 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 108 Downloads / 226 Views
"cost-neutral"? In an invited commentary2, Dr Gregory E. Simon of the Group Health Research Institute in Seattle (WA; USA) says the results of the CODIACS trial add "substantial evidence for the clinical benefit of depression screening and systematic treatment"; however, concluding that active treatment is "costneutral" may be a step too far in interpreting the finding of no significant difference in overall costs. Rather, the wide range in between-group overall cost differences in the 95% CIs suggests the sample is too small to provide an accurate cost estimate. Despite this, the overall results show that "delivering standardised services from a central location may be a viable (even preferable) alternative", says Simon. 1. Davidson KW, et al. Centralized, Stepped, Patient Preference-Based Treatment for Patients With Post-Acute Coronary Syndrome Depression: CODIACS Vanguard Randomized Controlled Trial. JAMA Internal Medicine : 1-8, 7 Mar 2013. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2013.915. 2. Simon GE. Benefits and Costs of Improving Depression Treatment in People With Heart Disease: Comment on "Centralized, Stepped, Patient PreferenceBased Treatment for Patients With Post-Acute Coronary Syndrome Depression". JAMA Internal Medicine : 1-2, 7 Mar 2013. Available from: URL: http:// dx.doi.org/10.1001/jamainternmed.2013.925. 801085616
1173-5503/10/0674-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 23 Mar 2013 No. 674
1
Data Loading...
